⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Official Title: A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin

Study ID: NCT01191892

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and gemcitabine hydrochloride is more effective with or without vandetanib as first-line therapy in treating urinary tract cancer. PURPOSE: This randomized phase II trial is studying giving carboplatin together with gemcitabine hydrochloride and to see how well it works when given with or without vandetanib as first-line therapy in treating patients with locally advanced or metastatic urinary tract cancer.

Detailed Description: OBJECTIVES: Primary * To determine the antitumor activity (as measured by progression-free survival) of carboplatin and gemcitabine hydrochloride with versus without vandetanib as first-line treatment in patients with locally advanced or metastatic urothelial cell cancer who are not suitable to receive cisplatin. Secondary * To determine the safety, feasibility, and tolerability of these regimens in these patients. * To determine the objective response rate. * To determine the overall survival of patients treated with these regimens * To assess the change of size of measurable lesions at 9 weeks of study therapy. OUTLINE: This is a multicenter study. Patients are stratified according to relevant factors. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and an oral placebo once daily on days 1-21. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patient receive carboplatin and gemcitabine hydrochloride as in arm I. Patients also receive oral vandetanib once daily on days 1-21. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Blood and urine samples may be collected for laboratory analysis at baseline and after completion of study. After completion of study treatment, patients are followed up at weeks 18, 26, 39, and 52. Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom

Wales Cancer Trials Unit, Cardiff, Wales, United Kingdom

Ayr Hospital, Ayr, , United Kingdom

Royal Bournemouth General Hospital, Bournemouth, , United Kingdom

Queens Hospital, Burton upon Trent, , United Kingdom

Velindre Hospital, City And County Of Cardiff, , United Kingdom

Western General Hospital, Edinburgh, , United Kingdom

Calderdale Royal Infirmary, Halifax, , United Kingdom

Huddersfield Royal Infirmary, Huddersfield, , United Kingdom

The Royal Lancaster Infirmary, Lancaster, , United Kingdom

St. James's University Hospital, Leeds, , United Kingdom

The Royal Free Hospital, London, , United Kingdom

St Marys Hospital, London, , United Kingdom

Charing Cross Hospital, London, , United Kingdom

Christie Hospital, Manchester, , United Kingdom

Mount Vernon Hospital, Northwood Middlesex, , United Kingdom

Churchill Hospital, Oxford, , United Kingdom

Weston Park Hospital, Sheffield, , United Kingdom

Southampton General Hospital, Southampton, , United Kingdom

Royal Surrey County Hospital, Surrey, , United Kingdom

The Royal Marsden Hospital, Surrey, , United Kingdom

Contact Details

Name: Robert Jones, MD

Affiliation: University of Glasgow

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: